Key result
Direct thrombin inhibitors and factor Xa inhibitors represent promising alternative anticoagulants for pediatric thrombosis, though current clinical experience is limited to early-phase studies.
This review highlights the need for and synthesizes current evidence on novel direct thrombin and factor Xa inhibitors for pediatric thrombosis management.
Should not yet change pediatric practice; leaves open the need for dedicated randomized trials.
There are many limitations with respect to anticoagulants currently used in standard paediatric practice for prophylaxis and treatment of thrombosis: heparin, low molecular-weight heparin, and warfarin. Factors such as pharmacokinetic and dosing variability are further exacerbated by properties of the immature haemostatic system of children. These shortcomings necessitate exploring alternative anticoagulants in the paediatric population. In this review, we discuss several promising direct thrombin inhibitors and factor Xa inhibitors, and synthesize relevant drug information and clinical experience from the limited available case reports, case series, and nonrandomized dose-finding trials published to date.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2010) conducted a review in Thrombosis. Direct thrombin inhibitors and factor Xa inhibitors vs. Heparin, low molecular-weight heparin, and warfarin was evaluated. Direct thrombin inhibitors and factor Xa inhibitors represent promising alternative anticoagulants for pediatric thrombosis, though current clinical experience is limited to early-phase studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: